These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

116 related items for PubMed ID: 3429376

  • 1. The emergence of resistance to ciprofloxacin during treatment of experimental Staphylococcus aureus endocarditis.
    Kaatz GW, Barriere SL, Schaberg DR, Fekety R.
    J Antimicrob Chemother; 1987 Nov; 20(5):753-8. PubMed ID: 3429376
    [Abstract] [Full Text] [Related]

  • 2. Efficacy of fleroxacin in experimental methicillin-resistant Staphylococcus aureus endocarditis.
    Kaatz GW, Seo SM, Barriere SL, Albrecht LM, Rybak MJ.
    Antimicrob Agents Chemother; 1989 Apr; 33(4):519-21. PubMed ID: 2499251
    [Abstract] [Full Text] [Related]

  • 3. Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis.
    Kaatz GW, Barriere SL, Schaberg DR, Fekety R.
    Antimicrob Agents Chemother; 1987 Apr; 31(4):527-30. PubMed ID: 3649202
    [Abstract] [Full Text] [Related]

  • 4. CI-960, a new fluoroquinolone, for therapy of experimental ciprofloxacin-susceptible and -resistant Staphylococcus aureus endocarditis.
    Kaatz GW, Seo SM, Lamp KC, Bailey EM, Rybak MJ.
    Antimicrob Agents Chemother; 1992 Jun; 36(6):1192-7. PubMed ID: 1329613
    [Abstract] [Full Text] [Related]

  • 5. Levofloxacin versus ciprofloxacin, flucloxacillin, or vancomycin for treatment of experimental endocarditis due to methicillin-susceptible or -resistant Staphylococcus aureus.
    Entenza JM, Vouillamoz J, Glauser MP, Moreillon P.
    Antimicrob Agents Chemother; 1997 Aug; 41(8):1662-7. PubMed ID: 9257737
    [Abstract] [Full Text] [Related]

  • 6. Efficacies of moxifloxacin, ciprofloxacin, and vancomycin against experimental endocarditis due to methicillin-resistant Staphylococcus aureus expressing various degrees of ciprofloxacin resistance.
    Entenza JM, Que YA, Vouillamoz J, Glauser MP, Moreillon P.
    Antimicrob Agents Chemother; 2001 Nov; 45(11):3076-83. PubMed ID: 11600359
    [Abstract] [Full Text] [Related]

  • 7. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-susceptible or methicillin-resistant Staphylococcus aureus.
    Fernandez-Guerrero M, Rouse M, Henry N, Wilson W.
    Antimicrob Agents Chemother; 1988 May; 32(5):747-51. PubMed ID: 3164989
    [Abstract] [Full Text] [Related]

  • 8. Efficacy of ciprofloxacin in treatment and prophylaxis of experimental Staphylococcus aureus endocarditis caused by a cloxacillin-tolerant strain and its non-tolerant variant.
    Voorn GP, Thompson J, Goessens WH, Schmal-Bauer WC, Broeders PH, Michel MF.
    J Antimicrob Chemother; 1994 Apr; 33(4):785-94. PubMed ID: 8056697
    [Abstract] [Full Text] [Related]

  • 9. Development of resistance to fleroxacin during therapy of experimental methicillin-susceptible Staphylococcus aureus endocarditis.
    Kaatz GW, Seo SM, Barriere SL, Albrecht LM, Rybak MJ.
    Antimicrob Agents Chemother; 1991 Aug; 35(8):1547-50. PubMed ID: 1929325
    [Abstract] [Full Text] [Related]

  • 10. Efficacy of levofloxacin for experimental aortic-valve endocarditis in rabbits infected with viridans group streptococcus or Staphylococcus aureus.
    Chambers HF, Xiang Q, Liu, Chow LL, Hackbarth C.
    Antimicrob Agents Chemother; 1999 Nov; 43(11):2742-6. PubMed ID: 10543757
    [Abstract] [Full Text] [Related]

  • 11. Treatment of Staphylococcus aureus endocarditis in rats with coumermycin A1 and ciprofloxacin, alone or in combination.
    Perronne CM, Malinverni R, Glauser MP.
    Antimicrob Agents Chemother; 1987 Apr; 31(4):539-43. PubMed ID: 3606060
    [Abstract] [Full Text] [Related]

  • 12. Comparative efficacy of trovafloxacin in experimental endocarditis caused by ciprofloxacin-sensitive, methicillin-resistant Staphylococcus aureus.
    Kim YS, Liu Q, Chow LL, Chambers HF, Täuber MG.
    Antimicrob Agents Chemother; 1998 Dec; 42(12):3325-7. PubMed ID: 9835540
    [Abstract] [Full Text] [Related]

  • 13. Efficacy of Telavancin in a rabbit model of aortic valve endocarditis due to methicillin-resistant Staphylococcus aureus or vancomycin-intermediate Staphylococcus aureus.
    Madrigal AG, Basuino L, Chambers HF.
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3163-5. PubMed ID: 16048918
    [Abstract] [Full Text] [Related]

  • 14. Ciprofloxacin and rifampin, alone and in combination, for therapy of experimental Staphylococcus aureus endocarditis.
    Kaatz GW, Seo SM, Barriere SL, Albrecht LM, Rybak MJ.
    Antimicrob Agents Chemother; 1989 Aug; 33(8):1184-7. PubMed ID: 2802547
    [Abstract] [Full Text] [Related]

  • 15. Efficacy of ofloxacin in experimental Staphylococcus aureus endocarditis.
    Kaatz GW, Seo SM, Barriere SL, Albrecht LM, Rybak MJ.
    Antimicrob Agents Chemother; 1990 Feb; 34(2):257-60. PubMed ID: 2327773
    [Abstract] [Full Text] [Related]

  • 16. Evaluation of ceftobiprole in a rabbit model of aortic valve endocarditis due to methicillin-resistant and vancomycin-intermediate Staphylococcus aureus.
    Chambers HF.
    Antimicrob Agents Chemother; 2005 Mar; 49(3):884-8. PubMed ID: 15728879
    [Abstract] [Full Text] [Related]

  • 17. In vivo efficacy of ceftaroline (PPI-0903), a new broad-spectrum cephalosporin, compared with linezolid and vancomycin against methicillin-resistant and vancomycin-intermediate Staphylococcus aureus in a rabbit endocarditis model.
    Jacqueline C, Caillon J, Le Mabecque V, Miègeville AF, Hamel A, Bugnon D, Ge JY, Potel G.
    Antimicrob Agents Chemother; 2007 Sep; 51(9):3397-400. PubMed ID: 17591849
    [Abstract] [Full Text] [Related]

  • 18. Efficacy of ciprofloxacin for experimental endocarditis caused by methicillin-susceptible or -resistant strains of Staphylococcus aureus.
    Carpenter TC, Hackbarth CJ, Chambers HF, Sande MA.
    Antimicrob Agents Chemother; 1986 Sep; 30(3):382-4. PubMed ID: 3640590
    [Abstract] [Full Text] [Related]

  • 19. Therapeutic effect of ME1036 on endocarditis experimentally induced by methicillin-resistant Staphylococcus aureus.
    Nagura J, Kijima K, Kurazono M, Takahata S, Sugano T, Tanaka Y, Hirai Y, Yamada K, Takayama Y, Shitara E, Yonezawa M.
    Antimicrob Agents Chemother; 2005 Aug; 49(8):3526-8. PubMed ID: 16048975
    [Abstract] [Full Text] [Related]

  • 20. Comparative activity of cloxacillin and vancomycin against methicillin-susceptible Staphylococcus aureus experimental endocarditis.
    Fernández Guerrero ML, de Górgolas M.
    J Antimicrob Chemother; 2006 Nov; 58(5):1066-9. PubMed ID: 16931540
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.